Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.

Yoon-Koo KangMin-Hee RyuMaria Di BartolomeoIan ChauHarry YoonJong Gwang KimKeun-Wook LeeSang Chul OhAtsuo TakashimaAnna KryzhanivskaYee ChaoLudovic EvesqueMichael SchenkerArlo McGinnYufan ZhaoJennifer LeeLucjan WyrwiczNarikazu Boku

Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2024)

This study did not meet its primary OS endpoint. Compared to placebo, rivoceranib improved PFS, ORR, and DCR. Rivoceranib also improved OS in a prespecified patient subgroup receiving ≥4th-line therapy.

Keyphrases

placebo controlled
double blind
phase iii
clinical trial
randomized controlled trial
phase ii
radiation therapy
papillary thyroid
mesenchymal stem cells
combination therapy